EA201500701A1 - Способ создания вакцины против микоплазм - Google Patents

Способ создания вакцины против микоплазм

Info

Publication number
EA201500701A1
EA201500701A1 EA201500701A EA201500701A EA201500701A1 EA 201500701 A1 EA201500701 A1 EA 201500701A1 EA 201500701 A EA201500701 A EA 201500701A EA 201500701 A EA201500701 A EA 201500701A EA 201500701 A1 EA201500701 A1 EA 201500701A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
immunogenic composition
mycoplasmic
mycoplasm
creating
Prior art date
Application number
EA201500701A
Other languages
English (en)
Other versions
EA032772B1 (ru
Inventor
Дайана М. Мёрфи Джордан
Брайан Томас Мартинсон
Кристине Маргарет Мьюленталер
Аксель Нойбауер
Арун В. Айер
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201500701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA201500701A1 publication Critical patent/EA201500701A1/ru
Publication of EA032772B1 publication Critical patent/EA032772B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описан среди прочего способ получения иммуногенной композиции, предназначенной для лечения и/или профилактики вызываемых микоплазмами инфекций у субъекта, заключающийся в том, что культивируют микоплазматические бактерии в системе на основе эукариотических клеток с пониженным содержанием сыворотки или без свиной сыворотки; получают антиген микоплазматических бактерий и добавляют фармацевтически приемлемый носитель. Кроме того, в заявке описана иммуногенная композиция, которую можно получать с помощью указанного способа, и способ иммунизации субъекта, заключающийся в том, что вводят указанную иммуногенную композицию субъекту.
EA201500701A 2012-12-28 2013-12-20 Способ получения иммуногенной композиции, предназначенной для лечения и/или профилактики вызываемых микоплазмами инфекций у субъекта EA032772B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746997P 2012-12-28 2012-12-28
PCT/US2013/076807 WO2014105672A1 (en) 2012-12-28 2013-12-20 Method of making a mycoplasma vaccine

Publications (2)

Publication Number Publication Date
EA201500701A1 true EA201500701A1 (ru) 2015-12-30
EA032772B1 EA032772B1 (ru) 2019-07-31

Family

ID=49917778

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500701A EA032772B1 (ru) 2012-12-28 2013-12-20 Способ получения иммуногенной композиции, предназначенной для лечения и/или профилактики вызываемых микоплазмами инфекций у субъекта

Country Status (23)

Country Link
US (2) US9273281B2 (ru)
EP (1) EP2938747B1 (ru)
JP (2) JP6122146B2 (ru)
KR (1) KR102153275B1 (ru)
CN (2) CN108379571A (ru)
AR (1) AR094648A1 (ru)
AU (1) AU2013370983B2 (ru)
BR (1) BR112015012711B1 (ru)
CA (1) CA2896298C (ru)
CL (1) CL2015001562A1 (ru)
DK (1) DK2938747T3 (ru)
EA (1) EA032772B1 (ru)
ES (1) ES2738100T3 (ru)
HU (1) HUE045015T2 (ru)
MX (1) MX361273B (ru)
MY (1) MY173223A (ru)
PH (1) PH12015501333A1 (ru)
PL (1) PL2938747T3 (ru)
PT (1) PT2938747T (ru)
SG (2) SG10201708028VA (ru)
TW (2) TWI618542B (ru)
UA (1) UA121193C2 (ru)
WO (1) WO2014105672A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
CN104981252B (zh) * 2012-12-28 2019-06-18 勃林格殷格翰动物保健有限公司 包含支原体抗原的免疫原性组合物
MY173223A (en) * 2012-12-28 2020-01-07 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
EP3408281A4 (en) * 2016-01-29 2019-08-14 Advanced Animal Diagnostics, Inc. METHOD AND COMPOSITIONS FOR DETECTING MYCOPLASMA EXPOSURE
CN109476711B (zh) * 2016-08-09 2023-08-08 财团法人农业科技研究院 防治猪鼻霉浆菌感染的组合物及生产该组合物的方法
WO2018144909A1 (en) * 2017-02-03 2018-08-09 The Administrators Of The Tulane Educational Fund Ophthalmic compositions for therapeutic and prophylactic uses
EP3632982A4 (en) 2017-05-24 2020-04-08 Mitsubishi Chemical Corporation MOLDING MATERIAL, AND FIBER REINFORCED COMPOSITE MATERIAL
US20220235313A1 (en) 2019-06-10 2022-07-28 ELANCO US, Inc. Mycoplasma media formulations
CN113201050B (zh) * 2020-08-06 2022-07-22 青岛诺安百特生物技术有限公司 一种金黄色葡萄球菌噬菌体穿孔素及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
GB1074920A (en) * 1965-04-21 1967-07-05 Pfizer & Co C Growth medium for mycoplasma pneumoniae and vaccine production
GB1137306A (en) * 1966-07-11 1968-12-18 Research Corp Inoculum for poultry
JPS5540568B2 (ru) 1972-10-05 1980-10-18
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5885823A (en) * 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US6825036B2 (en) * 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP3402304B2 (ja) * 2000-03-30 2003-05-06 株式会社微生物化学研究所 猫クラミジアワクチンの製造方法
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
PT2027873E (pt) 2001-07-02 2015-11-03 Zoetis Services Llc Vacinação de dose única com mycoplasma hyopneumoniae
EP1521592A2 (en) 2001-07-02 2005-04-13 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
IL159145A0 (en) 2001-08-28 2004-06-01 Pfizer Prod Inc Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions
TWI238721B (en) 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
US20080185755A1 (en) 2005-02-09 2008-08-07 Todd Deaville Method of Manufacturing a semi-Structural Panel
WO2006095431A1 (ja) * 2005-03-10 2006-09-14 Kyoritsu Seiyaku Corporation 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法
WO2007042827A2 (en) * 2005-10-14 2007-04-19 Ivan Petyaev Treatment and diagnosis of obligate intracellular pathogens
RU2487935C2 (ru) 2006-09-15 2013-07-20 Медиммун, Ллк. Линии клеток почки собаки майдин-дэрби (mdck), поддерживающие рост вирусов до высоких титров, и способ применения этих клеток в биореакторе
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
CL2008003202A1 (es) 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
BRPI0820341B1 (pt) 2007-11-06 2021-11-09 Zoetis Services Llc Composição imunogênica para uso na proteção de um animal contra uma doença associada a uma cepa virulenta de mycoplasma hyopneumoniae
MX2010007815A (es) 2008-01-23 2010-08-10 Boehringer Ingelheim Vetmed Composiciones inmunogenicas de mycoplasma hyopneumoniae contra pcv2 y metodos para producir composiciones de este tipo.
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
WO2009142086A1 (ja) 2008-05-23 2009-11-26 学校法人久留米大学 マイコプラズマ感染症用ワクチン組成物
BRPI0913954B1 (pt) 2008-06-27 2022-04-05 Zoetis Services Llc Composições de vacina e uso das mesmas
NZ591950A (en) 2008-10-31 2012-12-21 Boehringer Ingelheim Vetmed Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
AU2010251761B2 (en) 2009-05-19 2014-10-09 Bioproperties Pty Ltd A temperature sensitive vaccine strain of Mycoplasma hyopneumoniae and uses thereof
WO2011075379A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
US8112663B2 (en) 2010-03-26 2012-02-07 Lsi Corporation Method to establish redundancy and fault tolerance better than RAID level 6 without using parity
CN102258776B (zh) 2011-07-07 2013-07-10 普莱柯生物工程股份有限公司 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN104981252B (zh) 2012-12-28 2019-06-18 勃林格殷格翰动物保健有限公司 包含支原体抗原的免疫原性组合物
MY173223A (en) 2012-12-28 2020-01-07 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine

Also Published As

Publication number Publication date
TWI660736B (zh) 2019-06-01
US10512680B2 (en) 2019-12-24
AU2013370983A1 (en) 2015-05-21
TWI618542B (zh) 2018-03-21
JP2017145253A (ja) 2017-08-24
US20160136254A1 (en) 2016-05-19
MY173223A (en) 2020-01-07
US9273281B2 (en) 2016-03-01
JP6449364B2 (ja) 2019-01-09
ES2738100T3 (es) 2020-01-20
EP2938747A1 (en) 2015-11-04
CN108379571A (zh) 2018-08-10
CN104968365A (zh) 2015-10-07
BR112015012711A2 (pt) 2017-07-11
TW201438732A (zh) 2014-10-16
SG11201505089YA (en) 2015-07-30
KR102153275B1 (ko) 2020-09-09
HUE045015T2 (hu) 2019-11-28
SG10201708028VA (en) 2017-10-30
EA032772B1 (ru) 2019-07-31
KR20150100920A (ko) 2015-09-02
AR094648A1 (es) 2015-08-19
MX361273B (es) 2018-12-03
UA121193C2 (uk) 2020-04-27
US20140186394A1 (en) 2014-07-03
JP2016508983A (ja) 2016-03-24
PH12015501333A1 (en) 2015-09-02
CA2896298A1 (en) 2014-07-03
EP2938747B1 (en) 2019-05-01
PL2938747T3 (pl) 2019-11-29
PT2938747T (pt) 2019-08-01
AU2013370983B2 (en) 2019-09-26
CA2896298C (en) 2024-01-16
MX2015007730A (es) 2015-09-07
CN104968365B (zh) 2018-04-03
WO2014105672A1 (en) 2014-07-03
BR112015012711B1 (pt) 2022-08-16
CL2015001562A1 (es) 2016-06-24
TW201832777A (zh) 2018-09-16
JP6122146B2 (ja) 2017-04-26
DK2938747T3 (da) 2019-08-05

Similar Documents

Publication Publication Date Title
EA201500701A1 (ru) Способ создания вакцины против микоплазм
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
TR201910721T4 (tr) İnsan OX40'a yönelik spesifisiteye sahip olan antikor molekülleri.
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
MY161412A (en) Mycobacterium antigenic composition
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
GB2518813A (en) OMV vaccine against Burkholderia infections
NZ710744A (en) Methods for increasing immunoglobulin a levels
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
UA110024C2 (uk) Вакцинний вектор і спосіб посилення імунної відповіді
WO2013104995A3 (en) Compositions and methods for treating viral infections
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
RU2010129770A (ru) Вакцина против гриппа и способ ее получения
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
MX2015010110A (es) Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
EA201500700A1 (ru) Иммуногенная композиция, содержащая антигены микоплазм
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
MX369039B (es) Vacuna contra el circovirus porcino tipo 2.
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
BR112015012515A2 (pt) métodos para a indução de anticorpos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM